Advanced Biotherapy announced it has agreement with Battelle for the development and use monoclonal antibodies to treat humans and animals exposed to anthrax, plague and autoimmune diseases. Edmond Buccellato, CEO of Advanced Biotherapy, said the two companies will jointly participate in the “Initiatives for Proliferation Prevention” projects of the U.S. Department of Energy.